Essential Reads: Who is at Risk for Depression During the Perimenopause?
Although most women transition to menopause without experiencing psychiatric problems, an estimated 20% experience depression at some point during the menopausal transition.
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application for Zuranolone to the FDA in 2022
The FDA will review zuranolone for the treatment of depression in the first half of 2022.
Weekly Roundup for OCTOBER 29, 2021: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Essential Reads: A Comprehensive Review of Brexanolone for the Treatment of Postpartum Depression
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
For Women with Perinatal Mood and Anxiety Disorders, Can Nurses and Midwives Fill the Gaps in Mental Health Care?
Psychological interventions provided by nurses and midwives can significantly reduce the severity of perinatal depressive symptoms.
Weekly Roundup for OCTOBER 22, 2021: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.